Delivery Order SPE2DB22D1202-SPE2DB25FVHK3
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,706.08 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 20, 2025. This competitively awarded, firm fixed-price delivery order is set to be completed by August 21, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a critical pharmaceutical supplier to federal...
- The Defense Logistics Agency has awarded a delivery order valued at $20,132.84 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injectors with a completion date of August 26, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,232.68 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pen injectors on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed price contract was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,573.71 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on August 12, 2025. This firm fixed-price delivery order, which will be performed at the contractor's Conshohocken, Pennsylvania facility, represents a non-competitive set-aside and is scheduled for completion by August 13, 2025. The award falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,702.33 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound 12.5 mg/0.5 ml pen injectors. This firm fixed price, non-set-aside delivery order is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $1,538.71 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injectors on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $4,275.96 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors. This firm fixed price delivery order, which is scheduled for completion by September 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors with a ceiling value of $16,361.85. This firm fixed-price contract, which expires August 21, 2025, represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procedures with no set-aside designation, and performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,138.12 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 31, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract calls for delivery to be completed by August 1, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVHK3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,625.80 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. The contract represents a firm fixed price delivery order with an ultimate completion date of August 15, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.99 million and extending through December 2026. The IDC enables the company to supply a diverse portfolio of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and vaccines. Zepbound, a GLP-1 receptor agonist used for weight management, represents one of many therapeutic categories AmerisourceBergen delivers through its DLA contract framework to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 8/14/25 |